By
Latest Stories
Don’t miss our hot and upcoming stories
Could Lilly’s Oral GLP-1 Orforglipron Revolutionize Type 2 Diabetes Treatment? Complete Phase 3 Results Show Compelling Efficacy and Safety on Par with Injectable GLP-1 Therapies
Key Highlights Orforglipron Delivers Clinically Meaningful Glycemic and Weight ImprovementsThe ACHIEVE-1 Phase 3 trial established…
How Caris Life Sciences’ $7.6B IPO the Breakout Moment for AI-Powered TechBio in Oncology and Beyond?
Key Highlights AI Meets Molecular Medicine: A New TechBio Contender EmergesCaris Life Sciences’ successful IPO…
Is Eli Lilly’s $1.3B Acquisition of Verve the Turning Point for CRISPR-Based Cardiovascular Therapies?
Key Highlights Strategic Bet on Early-Stage InnovationEli Lilly’s acquisition of Verve Therapeutics for up to…
Is HEALWELL AI’s Acquisition of BioPharma Canada’s Biggest AI-Driven CRO Leap Yet—and a Blueprint for Future Clinical Trials?
Key Highlights HEALWELL Targets AI-Driven Scale in CRO with $14.4M BioPharma AcquisitionHEALWELL AI Inc. (TSX:…